Use of the radiation-inducible WAF1 promoter to drive iNOS gene therapy as a novel anti-cancer treatment

Journal of Gene Medicine

Volumn 6, Issue 6, 2004, Pages 673-680

  Worthington, Jenny ^a   McCarthy, Helen O ^a   Barrett, Eimear ^a   Adams, Catherine ^a   Robson, Tracy ^a   Hirst, David G ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Cancer gene therapy; Nitric oxide; Radiation inducible promoter; Radiosensitisation; WAF1

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; INDUCIBLE NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER THERAPY; COLON CARCINOMA; CONTROLLED STUDY; DERMIS; GENE EXPRESSION; GENE INDUCTION; GENE SEQUENCE; GROWTH CURVE; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PLOTS AND CURVES; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RADIATION DOSE; RADIATION EXPOSURE; RADIOSENSITIZATION; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; ANOXIA; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; MICE, INBRED BALB C; NEOPLASMS; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PROMOTER REGIONS (GENETICS); TISSUE DISTRIBUTION; X-RAYS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 3242798679     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.567     Document Type: Article

References (33)

1. Brune B, von Knethen A, Sandau KB. Nitric oxide and its role in apoptosis. Eur J Pharmacol. 1998; 351: 261-272.
2. Mitchell J, et al. Hypoxic mammalian cell radiosensitization by nitric oxide. Cancer Res 1993; 53: 5845-5848.
3. Janssens MY, Van den Berghe DL, Verovski VN, et al. Activation of inducible nitric oxide synthase results in nitric oxide-mediated radiosensitization of hypoxic EMT-6 tumor cells. Cancer Res 1998; 58: 5646-5648.
4. Wink DA, Cooke JA, Christodoulou D, et al. Nitric oxide and some nitric oxide donor compounds enhance the cytotoxicity of cisplatin. Nitric Oxide 1997; 1: 88-94.
5. Cooke JA, Krishna MC, Pacelli R, et al. Nitric oxide enhancement of melphalan-induced cytotoxicity. Br J Cancer 1997; 76: 325-334.
6. Kurimoto M, Endo S, Hirashima Y, et al. Growth inhibition and radiosensitization of cultured glioma cells by nitric oxide generating agents. J Neurooncol 1999; 42: 35-44.
7. Griffin RJ, Makepeace CM, Hur WJ, Song CW. Radiosensitization of hypoxic tumor cells in vitro by nitric oxide. Int J Radiat Oncol Biol Phys 1996; 36: 377-383.
8. Tozer GM, Shaffi KM. The response of tumour vasculature to angiotensin II revealed by its systemic and local administration to 'tissue-isolated' tumours. Br J Cancer 1995; 72: 595-600.
9. Abrams J. Mechanisms of action of the organic nitrates in the treatment of myocardial ischemia. Am J Cardiol 1992; 70: 30B-42B.
10. Kirkwood JM, Bender C, Agarwala S, et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol 2002; 20: 3703-3718.
11. Haviv YS, Curiel DT. Conditional gene targeting for cancer gene therapy. Adv Drug Deliv Rev 2001; 53: 135-154.
12. Robson T, Hirst DG. Transcriptional targeting in cancer gene therapy. J Biomed Biotech 2003; 2: 110-137.
13. Hallahan DE, Mauceri HJ, Seung LP, et al. Spatial and temporal control of gene therapy using ionizing radiation. Nat Med 1995; 1: 786-791.
14. Marples B, Scott SD, Hendry JH, et al. Development of synthetic promoters for radiation-mediated gene therapy. Gene Ther 2000; 7: 511-517.
15. Worthington J, Robson T, Murray M, et al. Modification of vascular tone using iNOS under the control of a radiation-inducible promoter. Gene Ther 2000; 7: 1126-1131.
16. Worthington J, Robson T, O'Keefe M, et al. Tumour cell radiosensitization using constitutive (CMV) and radiation inducible (WAF1) promoters to drive the iNOS gene: a novel suicide gene therapy. Gene Ther 2002; 9: 263-269.
17. Twentyman PR. A new mouse tumor model system (RIF-1) for comparison of end-point studies. J Natl Cancer Inst 1980; 64: 595-604.
18. Lamas S, Perez-Sala D, Moncada S. Nitric oxide: from discovery to the clinic. Trends Pharmacol Sci. 1998; 19: 436-438.
19. Brennan PA. The actions and interactions of nitric oxide in solid tumours. Eur J Surg Oncol 2000; 26: 434-437.
20. Lala PK, Chakraborty C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol 2001; 2: 149-156.
21. Juang SH, Xie Y, Xu L, et al. Use of retroviral vectors encoding murine inducible nitric oxide synthase gene to suppress tumorigenicity and cancer metastasis of murine melanoma. Cancer Biother Radiopharm 1997; 12: 167-175.
22. Soler MN, Bobe P, Benihoud K, et al. Gene therapy of rat medullary thyroid cancer by naked nitric oxide synthase II DNA injection. J Gene Med 2000; 2: 344-352.
23. Xu W, Liu L, Charles IG. Microencapsulated iNOS-expressing cells cause tumor suppression in mice. FASEB J 2002; 16: 213-215.
24. Messner UK, Ankarcrona M, Nicotera P, Brune B. p53 expression in nitric-oxide mediated apoptosis. FEBS Lett 1994; 355: 23-26.
25. Achison M, Hupp TR. Hypoxia attenuates the p53 response to cellular damage. Oncogene 2003; 22: 3431-3440.
26. Yook JI, Kim J. Expression of p21WAF1/CIP1 is unrelated to p53 tumour suppressor gene status in oral squamous cell carcinomas. Oral Oncol 1998; 34: 198-203.
27. Codegoni AM, Nicoletti MI, Buraggi G, et al. Molecular characterisation of a panel of human ovarian carcinoma xenografts. Eur J Cancer 1998; 34: 1432-1438.
28. Wasylyk C, Salvi R, Argentini M, et al. p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53. Oncogene 1999; 18: 1921-1934.
29. Sourvinos G, Spandidos DA. Decreased BRCA1 expression levels may arrest the cell cycle through activation of p53 checkpoint in human sporadic breast tumors. Biochem Biophys Res Commun 1998; 245: 75-80.
30. Karjalainen JM, Eskelinen MJ, Kellokoski JR, et al. p21 (WAF1/CIP1) expression in stage I cutaneous malignant melanoma: its relationship with p53, cell proliferation and survival. Br J Cancer 1999; 79: 895-902.
31. Shinoda J, Whittle IR. Nitric oxide and glioma: a target for novel therapy? Br J Neurosurg 2001; 15: 213-220.
32. Chinje EC, Stratford IJ. Role of nitric oxide in growth of solid tumours: a balancing act. Essays Biochem 1997; 32: 61-72.
33. Khare PD, Liao S, Hirose Y, et al. Tumor growth suppression by a retroviral vector displaying scFv antibody to CEA and carrying the iNOS gene. Anticancer Res 2002; 22: 2443-2446.